Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FNQ
|
|||
| Former ID |
DCL000726
|
|||
| Drug Name |
BIM23A760
|
|||
| Synonyms |
Lonapalene; LONAPALENE; RS-43179; 91431-42-4; UNII-WIF31Q54NJ; WIF31Q54NJ; CHEMBL36648; Lonapalenum; Lonapaleno; Lonapalenum [Latin]; Lonapaleno [Spanish]; Lonapalene (USAN); Lonapalene [USAN:INN]; RS 43179; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; AC1L1KN9; SCHEMBL120134; ZINC1630; DTXSID00238563; IFWMVQUGSGWCRP-UHFFFAOYSA-N; HY-U00156; BDBM50004677; CS-7197; ZB000377; D04770; 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acromegaly [ICD-11: 5A60.0; ICD-10: E22.0] | Phase 2 | [1], [2] | |
| Carcinoid syndrome [ICD-11: 5B10; ICD-10: E34.0] | Phase 2 | [1], [2] | ||
| Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Discontinued in Phase 3 | [3] | ||
| Company |
Ipsen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H15ClO6
|
|||
| Canonical SMILES |
CC(=O)OC1=C(C(=C(C2=C1C=CC(=C2)Cl)OC(=O)C)OC)OC
|
|||
| InChI |
1S/C16H15ClO6/c1-8(18)22-13-11-6-5-10(17)7-12(11)14(23-9(2)19)16(21-4)15(13)20-3/h5-7H,1-4H3
|
|||
| InChIKey |
IFWMVQUGSGWCRP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 91431-42-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. | |||
| REF 2 | Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2008 Jun;13(2):273-93. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003802) | |||
| REF 4 | Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. | |||
| REF 5 | Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J Invest Dermatol. 1990 Jul;95(1):50-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.